Navigation Links
Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
Date:7/1/2008

HELSINKI, July 1 /PRNewswire/ -- The emergence of multidrug-resistant Gram-negative bacteria has necessitated the use of polymyxins as the agents of last resort despite their known nephrotoxicity. Now Northern Antibiotics Ltd, a Finnish biotech company, has developed novel polymyxin derivatives which in early preclinical studies show signs of lower nephrotoxicity.

The derivatives contain three positive charges only, while polymyxin B and colistin have five. They bind to the isolated brush-border membrane of rat kidney at an affinity which is only 1/5-1/7 of that for polymyxin B. In vivo rat studies also show remarkable differences in parameters that are considered to indicate early kidney damage, such as serum urea nitrogen, albuminuria and cylindrouria.

The derivatives fall in to two groups that differ in their mode of action. The lead compound of the first group, NAB 7061, sensitizes enteric bacteria to other antibiotics. For example, it reduces the minimum inhibitory concentration (MIC) of clarithromycin for ESBL-producing strains of Escherichia coli by a factor of 250-750. NAB 739, the lead compound of the second series, acts directly against enteric bacteria. For E. coli (including ESBL-producing strains) the MIC90 is identical to that of polymyxin B. While NAB 739 is already alone highly active against multidrug-resistant strains of Acinetobacter baumannii, it also at very low subinhibitory concentrations sensitizes this bacterium to other antibiotics. A paper entitled "Novel polymyxin derivatives carrying only three positive charges are effective antibacterial agents" was published ahead of print on June 30, 2008 (Antimicrob. Agents Chemother., doi:10.1128/AAC.00405-08).

"The efficacy of both lead compounds has been verified using an experimental E. coli peritonitis model in mice, and we are now talking to potential partners to further develop and eventually commercialize these two lines of novel compounds," says Professor Martti V
'/>"/>

SOURCE Northern Antibiotics Ltd
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Northern California Foot and Ankle Center Santa Rosa Enrolling Patients With Chronic Diabetic Foot Ulcers for Matrix Clinical Research Trial
2. ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics
3. For Most, Good Oral Care Does More Than Antibiotics to Prevent Dental-Related Heart Problems, Reports the Harvard Heart Letter
4. Nventa Develops Proprietary Vaccine Adjuvant
5. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
6. DG041 Blocks Platelet Aggregation Through a Novel Mechanism and does not Increase Bleeding Time When Given Alone or with Plavix(TM) or Aspirin
7. Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome
8. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
9. European Enrollment Begins in Pivotal Phase 3 Trial of Novel Combination Medicine Developed by Cogentus Pharmaceuticals
10. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
11. New Data on MAGE-A3 Cancer Immunotherapy Support Potential Novel Options of Treating Non-Small Cell Lung Cancer and Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... 2015  InfuSystem Holdings, Inc. (NYSE MKT: INFU), a ... for the U.S. healthcare industry, today announced that it ... 12, 2015 after the market closes. The ... on Tuesday, May 12, 2015 at 4:30 p.m. Eastern ... participate in this call, please dial in toll-free 1-800-446-1671 ...
(Date:5/5/2015)... 2015  Omron Healthcare, Inc., the leader in home blood ... pressure monitor and scale with connectivity via smartphone, tablet, or ... With the population ... remote patient monitoring has become increasingly important for not only ... "These easy to use ...
(Date:5/5/2015)... May 5, 2015 Omeros Corporation (NASDAQ: ... discovering, developing and commercializing both small-molecule and protein ... targeting inflammation, coagulopathies and disorders of the central ... issue its first quarter 2015 financial results for ... May 11, 2015, after market close. Omeros management ...
Breaking Medicine Technology:New Blood Pressure Monitor And Scale Allow Chronically Ill Patients To Stay At Home While Connected To Healthcare Professionals 2New Blood Pressure Monitor And Scale Allow Chronically Ill Patients To Stay At Home While Connected To Healthcare Professionals 3Omeros Corporation to Announce First Quarter 2015 Financial Results on May 11, 2015 2
... Inc. (Nasdaq: TNGN ), a leader in ... clinical assessment of the first implanted bladder cancer patient ... expected and has permitted the second patient to be ... trial calls for each of the first few patient ...
... A new white paper urges medical device and ... validation program as a means of preventing the ... terminally sterilized medical products are based on years of ... of failures occur due to inadequate package validation programs," ...
Cached Medicine Technology:Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients 2Tengion Advances Clinical Trial for Neo-Urinary Conduit™ in Bladder Cancer Patients 3New White Paper: Having a Solid Package Validation Program Can Prevent Failure of Combination Products 2New White Paper: Having a Solid Package Validation Program Can Prevent Failure of Combination Products 3
(Date:5/5/2015)... May 05, 2015 Buckeye Health Plan ... new CEO and plan president of Buckeye Health Plan. ... the position immediately. , Hill has more than 28 ... the Pacific Northwest, from managed care to large health ... and CEO of HealthPlus of Michigan, a health plan ...
(Date:5/5/2015)... (PRWEB) May 05, 2015 Igantia ... San Francisco, leads an international initiative to examine key ... extend the human lifespan. Scientists at Igantia believe ... women, from the initiation of her menstrual cycle to ... mechanism for aging and, ultimately, extend the lifespan. ...
(Date:5/5/2015)... 2015 HealthSlide, Inc ., ... solutions for hospitals nationwide, has announced the launch ... CIOs and CTOs can access the calculator on ... both initial and ongoing savings of switching to ... nation’s hospitals pay an average of $300,000 a ...
(Date:5/5/2015)... 05, 2015 After record-breaking sales of ... 2014, Walgreens introduces the Cookies & Cream flavor at ... Extend Nutrition has continually raised the bar for nutritional ... combined with an unprecedented nutritional profile, backed by international ... Extend Nutrition will launch additional new products and expand ...
(Date:5/5/2015)... May 05, 2015 Every year, news articles ... Turns out, the worst dry eye season is spring, also ... in most of the United States. The only season offering ... advocate Sharon Kleyne, host of the Sharon Kleyne Hour™ Power ... her radio show of May 11, 2015. Kleyne is the ...
Breaking Medicine News(10 mins):Health News:Buckeye Health Plan Announces New Chief Executive Officer 2Health News:Buckeye Health Plan Announces New Chief Executive Officer 3Health News:Igantia Announces Digital Initiative to Decode Longevity 2Health News:HealthSlide Launches ROI Cost Calculator 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 2Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 3Health News:Nationwide Launch of Extend Nutrition’s Newest Bar Flavors Follows Most Successful New Item Sales in Company History 4Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 2Health News:Nature’s Tears EyeMist tear film supplement soothes dry eye caused by spring pollen season, reports inventor Sharon Kleyne 3
... According to findings of a recent study researchers say bypass ... for many patients // with blocked heart arteries . ... on-pump (work of the heart is shifted to a mechanical ... still beating) surgery. Results of the surgeries were evaluated one ...
... in addition to medication show an improved clinical recovery ... to a new study. ,Researchers examined 126 patients ... in the middle cerebral artery. All the patients were ... of symptom onset. 63 patients were randomly assigned to ...
... cardiovascular disease risk factors, which include high blood pressure, impaired ... the condition is made if you have three out of ... risk for cardiovascular disease. According to a new study, starting ... add extra risk. ,Based on findings of the study ...
... and one of the most frequent causes of indigestion. Typical ... cases. Smoking and a high salt intake significantly increase the ... study. ,Results of the study showed that people ... 70-percent more likely to have acid reflux than non-smokers. Those ...
... more over several years puts one at greater risk for heart ... weight . ,Researchers studied nearly 2,500 adults between ages ... or more during the study, and 20 percent of these people ... and diabetes. But only 4 percent of those who didn't gain ...
... new study shows that not being in optimum cardiovascular health ... say researchers .// ,Researchers say they have found ... cognitive impairment in the elderly. The conditions of metabolic syndrome ... blood glucose levels, high blood pressure, and low levels of ...
Cached Medicine News:
Legionella IgG/M ELISA....
Measles IgM ELISA....
... The Wampole EBV ELISA test ... of assays for the determination ... tests for Viral Capsid Antigen ... Nuclear Antigen (EBNA). Most Wampole ...
Toxo IgG ELISA. All Wampole ELISA kits include the following: 12 x 8 well strips with breakaway wells, sample diluent, controls and calibrators, conjugate, TMB substrate, wash buffer, stop solution,...
Medicine Products: